Pega Named a Leader in AI Decisioning Platforms by Independent Research Firm

Pega's AI-powered decisioning and workflow automation capabilities recognized with highest scores possible in all strategy criteria
WALTHAM, Mass., June 10, 2025--(BUSINESS WIRE)--Pegasystems Inc. (NASDAQ: PEGA), The Enterprise Transformation CompanyTM, today announced Forrester Research has named Pega a Leader in The Forrester Wave™: AI Decisioning Platforms, Q2 2025 (1). Pega earned the highest score in the strategy category, including the highest scores possible in the vision, innovation, roadmap, partner ecosystem, adoption, and supporting services and offerings criteria.
The report states: "Pega's approach is timeless — it aims to build a platform that enables enterprises to 'design for people, build for change.' The company is now using AI to do that, infusing it into every platform capability, including Pega GenAI BlueprintTM, which enables users to generate full decisioning workflows and build AI agents using natural language. Pega is firing on all cylinders with its superior vision, innovation, roadmap, partner ecosystem, adoption, and support services."
On Pega's platform capabilities, the report states: "Pegasystems' platform excels in data modeling and integration, enabling enterprises to effectively create a simplified data abstraction layer for decisioning applications. Governance capabilities, including lifecycle management and observability, facilitate compliance and mission-critical monitoring. The platform's extensible architecture enables customers to integrate with enterprise systems and offers an on-ramp to Pegasystems' partners to add industry-specific modules."
The report also found that reference customers report "implementing the Pega platform broke down customer data silos, unified processes, and most importantly, enabled hyper-personalization for millions of consumers," noting that "Pega turns executives into customer-centric heroes."
This Forrester Wave report evaluated 15 vendors across 18 criteria spanning current offering, strategy, and also customer feedback. Pega received the highest scores possible for the following criteria: data modeling, data integration, decision testing, cohesive experience, lifecycle, observability, and extensibility.
Forrester evaluated Pega InfinityTM, Pega's suite of solutions for AI-powered decisioning and workflow automation, including Pega PlatformTM, a powerful low-code platform combining AI-powered decisioning and workflow automation to help enterprises efficiently build scalable, intelligent apps. It also analyzed Pega Customer Decision HubTM, an AI-powered, real-time decisioning engine that delivers hyper-personalized next-best-actions to optimize customer engagement. Additionally, the evaluation recognized Pega Blueprint, Pega's genAI-powered design agent that transforms client goals and documentation into modern, agent-driven app workflows using Pega's best practices. These tools provide a comprehensive approach to AI decisioning for Pega clients to achieve measurable, optimized business outcomes.
This report is among Pega's many recent analyst recognitions for its customer engagement, enterprise AI, and workflow automation capabilities. Recently, Pega was recognized as a Leader in the Gartner® Magic Quadrant for Process Mining Platforms 2025 (2), Gartner® Magic Quadrant for CRM Customer Engagement Center (CEC) 2024 (3), and the Gartner® Magic Quadrant™ for Enterprise Low-code Application Platforms (LCAP) (4). It was also named a Leader in The Forrester WaveTM: Customer Relationship Management Software, Q1 2025 (5), The Forrester Wave: Real-Time Interaction Management, Q1 2024 (6), The Forrester WaveTM: Customer Service Solutions 2024 (7), and The Forrester WaveTM: Task-Centric Automation Software, Q4 2024 (8). For more background on these and additional analyst reports, visit www.pega.com/analyst-reports.
Quotes & Commentary:"Today's organizations need precise, adaptive AI that empowers both humans and AI agents to make fast, context-aware decisions," said Kerim Akgonul, chief product officer, Pega. "Pega's AI decisioning capabilities are designed as a surgical, statistical engine that continuously learns and optimizes workflows—whether it's guiding a customer interaction or automating a process. This recognition reinforces our commitment to delivering the right AI for the right purpose, enabling our clients to build self-optimizing systems that drive meaningful, transformational outcomes."
Supporting Resources:
Report access: The Forrester Wave™: AI Decisioning Platforms, Q2 2025
Solution background: Pega Infinity
Solution background: Pega Blueprint
Solution background: Pega Customer Decision Hub
Solution background: Pega Platform
Forrester Research, "The Forrester Wave™: AI Decisioning Platforms, Q2 2025," by Mike Gualtieri with contributions from Sudha Maheshwari, Bardia Razzaghi, and Jen Barton, June 10, 2025
Gartner, Inc., "Magic Quadrant for Process Mining Platforms, Q1, 2025," by Tushar Srivastava, Marc Kerremans, David Sugden, April 16, 2025
Gartner, Inc., "Magic Quadrant for the CRM Customer Engagement Center (CEC) 2024," by Pri Rathnayake, Wynn White, Drew Kraus, December 2024
Gartner, Inc., "Magic Quadrant for Enterprise Low-Code Application Platforms," by Oleksandr Matviskyy, Kyle Davis, and Akash Jain, October 16, 2024
Forrester Research, "The Forrester Wave™: Customer Relationship Management Software, Q1 2025," by Kate Leggett, with contributions from Linda Ivy-Rosser and Faith Born, March 21, 2025
Forrester Research, "The Forrester Wave™: Real-Time Interaction Management, Q1 2024" by Rusty Warner, February 26, 2024
Forrester Research, "The Forrester Wave™: Customer Service Solutions, Q1 2024" by Kate Leggett, March 6, 2024
Forrester Research, "The Forrester Wave™: Task-Centric Automation Software, Q4 2024" by Bernhard Schaffrik, Pascal Matzke, Faith Born, and Kara Hartig
Forrester does not endorse any company, product, brand, or service included in its research publications and does not advise any person to select the products or services of any company or brand based on the ratings included in such publications. Information is based on the best available resources. Opinions reflect judgment at the time and are subject to change. For more information, read about Forrester's objectivity here.
About PegasystemsPega is The Enterprise Transformation CompanyTM that helps organizations Build for Change® with enterprise AI decisioning and workflow automation. Many of the world's most influential businesses rely on our platform to solve their most pressing challenges, from personalizing engagement to automating service to streamlining operations. Since 1983, we've built our scalable and flexible architecture to help enterprises meet today's customer demands while continuously transforming for tomorrow. For more information on Pega (NASDAQ: PEGA), visit www.pega.com.
All trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610448876/en/
Contacts
Press Contact: Ilena RyanPegasystemsilena.ryan@pega.com

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

6 hours ago

• Yahoo

Pegasystems price target raised to $50 from $47.50 at DA Davidson

DA Davidson analyst William Jellison raised the firm's price target on Pegasystems (PEGA) to a split-adjusted $50 from $47.50 and keeps a Neutral rating on the shares. The firm cites the company's recently-announced $700M free cash flow goal for 2028 and believes the required performance from Pega Cloud is both ambitious and achievable, which it views 'favorably', the analyst tells investors in a research note. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on PEGA: Disclaimer & DisclosureReport an Issue Pegasystems CEO sells $3.18M in common stock Pegasystems Confirms Two-for-One Stock Split Pegasystems shareholders approve two-for-one stock split Pegasystems price target raised to $131 from $116 at Citi Pegasystems price target raised to $112 from $101 at Rosenblatt Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Business Wire

7 hours ago

• Business Wire

GE HealthCare drives innovation in theranostics with latest technological advances

CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.

Hamilton Spectator

10 hours ago

• Hamilton Spectator

Jetoptera Executes FETT for FTC-250 at Paris Air Show 2025

PARIS, June 21, 2025 (GLOBE NEWSWIRE) — On the occasion of Jetoptera's debut at the Paris Air Show 2025, we are proud to announce the successful completion of the first test of the engine that will power the J-500, the 500-lb VTOL cargo unmanned aircraft system Jetoptera is developing in collaboration with Eanan Al Samma, for the United Arab Emirates (UAE) market. The First Engine To Test (FETT) was evaluated at the VAN DER LEE Turbo Systems facilities in Zaandam, The Netherlands. The 250 kW turbocompressor, that is the heart of the Fluidic Propulsive System™, is a two-shaft engine using a free turbine that is mechanically coupled to a two-stage axial compressor designed to produce the appropriate flow rates and pressure ratios required by the FPS™. 'The FETT demonstrated a very smooth startup and operability when operated in a turbofan mode. The engine was instrumented in this configuration, to monitor pressure and temperature as well as thrust produced. The next step includes the performance mapping of the turbocompressor, followed by the integration with the FPS™ onto the J-500 airframe,' said Dr Andrei Evulet, CEO/CTO of Jetoptera, Inc. The J-500 prototype is developed specifically for the UAE and MENA market and will be uniquely enabled by the FPS™ to perform unmanned cargo missions with VTOL and unmatched speed, low noise, and reliability thanks to the patented propulsion system. The modularity of the FTC-250 system allows its components to operate in turbojet, turbofan and FPS™ modes. Jetoptera and Eanan Al Samma thank Parametric Solutions, Inc. and VAN DER LEE Turbo Systems for their critical support in the design and manufacturing of the unique FTC-250 architecture in record time. For information about this press release please contact Todd Newton todd@ Jetoptera, Inc. Facebook: LinkedIn: A photo accompanying this announcement is available at